Seizure susceptibility of neuropeptide-Y null mutant mice in amygdala kindling and chemical-induced seizure models.
Shannon
Harlan E
HE
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. H.Shannon@Lilly.com
Yang
Lijuan
L
D000679:Amygdala / Q000502:physiology*; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D003292:Convulsants / Q000633:toxicity*; D004567:Electrodes, Implanted; D018690:Excitatory Amino Acid Agonists; D007608:Kainic Acid; D007696:Kindling, Neurologic / Q000502:physiology*; D000077287:Levetiracetam; D051379:Mice; D018345:Mice, Knockout; D009478:Neuropeptide Y / Q000235:genetics* / Q000502:physiology*; D010862:Pilocarpine; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced / Q000209:etiology / Q000235:genetics*
D000927:Anticonvulsants; D003292:Convulsants; D018690:Excitatory Amino Acid Agonists; D009478:Neuropeptide Y; D010862:Pilocarpine; D002220:Carbamazepine; D000077287:Levetiracetam; D007608:Kainic Acid; D010889:Piracetam